spacer
home > white papers > Translating Cancer Genomics Into A Personalised Approach For Cancer Patients - PRA Health Sciences (PRA)
WHITE PAPERS
logo_PRA_Healthk.jpg

PRA Health Sciences (PRA)

phone +44 (118) 918-1000
email prahealthsciences@prahs.com
web http://www.prahs.com
email Green Park, 500 South Oak Way, Reading, RG2 6AD UK

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patientís particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
Translating Cancer Genomics Into A Personalised Approach For Cancer Patients
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Distributed Control System Facilitates Expansion for New Drugs Produced by Contract Manufacturing Organisation

Combatting the pandemic has highlighted the importance of the partnership between biopharma organizations and the contract manufacturing organizations (CMOs) that must flexibly handle outsourced production, which can come suddenly and often must quickly be ramped up.
More info >>


White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement